Trade BioNTech ^BNTX

Moderna Rallies 8% on 2026 Melt-Up Momentum Even While BioNTech and Merck Stay Flat

Analysts Set BioNTech SE Sponsored ADR (NASDAQ:BNTX) Target Price at $127.44 - Markets Daily

Insider Selling: BioNTech (NASDAQ:BNTX) CEO Sells 36,000 Shares of Stock - Markets Daily

BioNTech (NASDAQ:BNTX) CEO Ugur Sahin Sells 37,000 Shares

BioNTech (NASDAQ:BNTX) CEO Sells $3,520,080.00 in Stock - Stock Observer

New MUC16-targeting ADC reported in Biontech patent

BioNTech SE Sponsored ADR $BNTX Shares Sold by Carmignac Gestion

Ugur Sahin Sells 31,500 Shares of BioNTech (NASDAQ:BNTX) Stock - Zolmax

Insider Selling: BioNTech (NASDAQ:BNTX) CEO Sells 31,500 Shares of Stock - Markets Daily

Carmignac Gestion Has $7.45 Million Stake in BioNTech SE Sponsored ADR $BNTX - Daily Political

BMO lowers Amgen, BioNTech to Market Perform as risk-reward shifts

BioNTech Shares Fall After BMO Downgrade and Price Target Cut

Swapped Lives: The 15-Year Fork in the Road Between Moderna and BioNTech

BioNTech Ended a Cancer Vaccine Trial. What Does it Mean for its mRNA Strategy?

Unlocking Opportunity: Dominate the Cancer Vaccine Market with Confidence Now Available. Tracks 960+ Organizations and 2,100+ Drugs Across the Full Cancer Vaccine Pipeline

BioNTech's Promising Oncology Pipeline Is Now in Late-Stage Development | Morningstar

This $26 Billion Biotech Name Is Ripe for a Covered-Call Trade

Pfizer (PFE) Stock Looks Overvalued After Updated COVID Vaccine Approval

BioNTech (BNTX) Stock Looks Above Fair Value As Shares Fell 70%

BioNTech vs. Moderna: Which Is the Better Cancer Vaccine Stock to Buy Now?

Is BioNTech Stock a No-Brainer Buy on the Dip?

BioNTech (BNTX) Halts Cancer Trial, Is The 15% Undervaluation Still Credible?

Pfizer (PFE) Following FDA Vaccine Approval Has Fair Value Back In Focus

BioNTech (NASDAQ:BNTX) Given New $136.00 Price Target at Canaccord Genuity Group - Markets Daily

Pfizer Inc. (NYSE:PFE) Receives $28.28 Consensus Target Price from Analysts - Markets Daily

Canaccord Genuity Group Cuts BioNTech (NASDAQ:BNTX) Price Target to $136.00 - Stock Observer

Headlands Technologies LLC Takes Position in BioNTech SE Sponsored ADR $BNTX - Daily Political

Investors Purchase High Volume of BioNTech Put Options (NASDAQ:BNTX)

Pfizer (NYSE:PFE) Stock Price Down 1% - Here's What Happened - Markets Daily

Freestone Grove Partners LP Boosts Position in Pfizer Inc. $PFE

Van ECK Associates Corp Has $399.36 Million Stock Holdings in Pfizer Inc. $PFE - Stock Observer

Freestone Grove Partners LP Buys 254,644 Shares of Pfizer Inc. $PFE - Daily Political

BioNTech (BNTX) Ended A Phase 2 Colorectal Cancer Trial

BioNTech Kills a Cancer Trial Roche Helped Build

BioNTech Terminates Phase 2 Colorectal Cancer Clinical Trial; Shares Fall

FDA Approves Seasonal Covid-19 Vaccines From Moderna, Pfizer, BioNTech, Novavax - Update | Morningstar

BioNTech Target of Unusually Large Options Trading (NASDAQ:BNTX) - Zolmax

Stock Traders Buy Large Volume of Put Options on BioNTech (NASDAQ:BNTX)

FDA approves updated COVID vaccine for seniors and high-risk adults

BioNTech Tumbles 8% as Colorectal Cancer Vaccine Trial Fails, Moderna Drops 6%, Pfizer Holds Flat

BioNTech drops 10% on mRNA trial failure, highlighting Moderna contrast

Markets News, Aug. 28, 2026: Indexes Close Higher for Week; Marvell Weighs on Tech Stocks; Bond Yields Rise After Warsh Speech

Best Biotech Stocks To Research - August 28th - Daily Political

The Bull Case For Pfizer (PFE) Could Change Following New COVID And Lyme Vaccine Milestones - Learn Why

FDA approves updated Covid-19 vaccines

FDA Approves Seasonal Covid-19 Vaccines From Moderna, Pfizer, BioNTech | Morningstar

BioNTech (BNTX) Rallied on Moderna's Win. Does a Competitor's Success Validate its Oncology Pipeline?

Moderna Drops 7% Despite a Fresh Wolfe Research Upgrade, BioNTech Slips

$7+ Billion mRNA Vaccines Market Outlook, 2035: Opportunities, Strategies, Challenges

Moderna Rallies 11%, BioNTech Ticks Up: Is the mRNA Trade Down to One Name?

Cancer Vaccine Breakthrough Lifts 5 Biotech Names. Here's Who's Best Positioned.

Moderna Sinks 7% as Traders Book Profits on a 392% Year-to-Date Surge; BioNTech Drops 4%, Merck Slips

BioNTech Moved Higher as the Broader Biotech Sector Hit a Post-Pandemic Peak, but BNTX Stock Needs Stronger Fundamentals to Keep Climbing

BioNTech (BNTX) Is Up 25.2% After First-in-Class Pumitamig Plus B7H3 ADC Lung Data - What's Changed

BioNTech (BNTX) Stock Looks Fully Priced As It Rebounds From A 67% Fall

BioNTech (BNTX) Presents New Lung Cancer Data, Is The Stock Already Fully Valued?

Moderna Rallies 8%, BioNTech Climbs 4% as the mRNA Trade Whipsaws for a Third Session

BioNTech (NASDAQ:BNTX) Shares Up 7.4% - Here's What Happened - Daily Political

Moderna Sinks 18% After 177% Cancer Vaccine Rally, BioNTech Falls 4%, Merck Slips

Flossbach Von Storch SE Makes New Investment in BioNTech SE Sponsored ADR $BNTX

BioNTech Sees Unusually High Options Volume (NASDAQ:BNTX)

BioNTech (NASDAQ:BNTX) Shares Gap Up - Here's Why

Moderna Rockets 93%, Merck Jumps 7% as Melanoma Therapy Meets Primary Goal in Phase 3 Trial

Biotech Stocks To Keep An Eye On - August 19th - Daily Political

BioNTech SE Sponsored ADR (NASDAQ:BNTX) Receives Average Rating of "Moderate Buy" from Brokerages

BioNTech SE Sponsored ADR (NASDAQ:BNTX) Receives $127.81 Average Target Price from Analysts - Daily Political

BioNTech's oncology pivot comes with a new CEO

BioNTech SE Sponsored ADR (NASDAQ:BNTX) Given Average Recommendation of "Moderate Buy" by Brokerages